Laurus Labs, a major player in the pharmaceutical and biotechnology space, has been gaining traction among investors due to its strong fundamentals and sectoral potential.
Motilal Oswal Financial Services has reiterated its BUY recommendation on Galaxy Surfactants Limited (GALSURF) with an upgraded target price of Rs 3,865, representing a 46% upside.
Argus Research maintains its Buy rating on Copart Incorporated (NASDAQ: CPRT), raising its price target to $70 from $58, representing a 12% upside potential from current levels.